Gastrointestinal epidemiologi – Jonas Ludvigssons forskargrupp

Vi studerar orsaker och konsekvenser av magtarmsjukdomar (inklusive levern, gallblåsan och bukspottskörtlen) genom att länka patologidata med nationella hälsoregister I Sverige.

En del av:
Jonas Ludvigssons forskargrupp

Gruppen för gastrointestinal (GI) epidemiologi fokuserar på forskning som rör magtarmsystemet. Det mesta av vår forskning utgår från den så kallade ESPRESSO-studien som du kan läsa mer om under en egen flik på denna sida. Genom att länka patologidata kan vi undersöka en rad tillstånd och sjukdomar inklusive förstadier till cancer brain-gut axis, olika sjukdomsfenotyper etc. 

Vår forskning har publicerats i bland annat the New Engl J Medicine, Lancet, JAMA, the BMJ, Annals of Internal Medicine, Gastroenterology och Gut.

Publikationer

Alla gruppmedlemmars publikationer

Finansiering

Forskningsbidrag

  • Inflammatorisk tarmsjukdom, inflammation och risk för hjärtsjukdom
    Hjärt-Lungfonden
    1 January 2025 - 31 December 2027
  • Autism in Preterm Birth
    NICHD
    1 September 2024 - 31 August 2029
  • Consensus Statements for the Use of Routinely Collected Health Data in Inflammatory Bowel Disease Research
    Canadian Institutes of Health Research
    1 June 2022 - 31 May 2023
  • Swedish Research Council
    1 December 2021 - 30 November 2025
    Autism Spectrum Disorder (ASD) risk is primarily of genetic origins. One source through which environmental effects may be influential is preterm birth (PTB
    birth &lt
    37 weeks gestation) which constitutes 6% of all births in Sweden (10% world wide). PTB is primarily of environmental origin, due to disease in the pregnant woman or her fetus. The processes underlying PTB may initiate ASD. This hypothesis has not been previously studied. If true, the heritability of ASD may be much lower in PTB children suggesting that PTB defines a subset of the general population where environmental risk play the major role for ASD risk.The goal of our project is to examine the ASD-etiology in PTB children and test if the etiology is different compared to term-born
    identify risk factors for ASD in PTB children, and to estimate the public health consequences of these factors.We will create a cohort of all Swedish children born 1995-2014 using the national registers, replicate results in Finland and examine genetic markers in a Swedish genetic sample.Aims are: (1) Determine the epidemiology and risk factors for ASD in PTB children. (2) Test if the risk factors in aim 1 are due to confounding, and estimate their public health consequences. (3) Compare ASD susceptibility in PTB and term-born children using both family data and molecular genetic data. (4) Explore potentials for risk prediction in a clinical cohortThis will be the most systematic investigation ASD-etiology in PTB children to date.
  • Inflammatory bowel disease and cancer risk - a moving target in an era of new immunomodulatory therapies
    Swedish Research Council
    1 January 2021 - 31 December 2024
  • Swedish Cancer Society
    1 January 2021
    Every year, one in three Swedes seeks care for gastrointestinal problems. A significant number have cancer, others have gastrointestinal diseases where there may be an increased risk of cancer. In our study, we will study: (1) gastrointestinal/liver disease and risk of cancer, (2) risk factors for gastrointestinal cancer, and (3) the prognosis of such cancer. Unlike the majority of previous international studies, by linking data from tissue samples from intestine/liver to Sweden's national health register, we will be able to study the entire population. It makes it possible to calculate precise cancer risks for average patients. We have established a brand new register of more than 2 million Swedes (Espresso), and will study the RISK OF CANCER in irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) such as e.g. Crohn's disease and ulcerative colitis, but also in liver diseases, the esophageal disease eosinophilic esophagitis
    RISK FACTORS FOR GASTROINTESTINAL CANCER such as colon cancer, and whether mucosal healing and medication can protect against IBD and liver cancer
    and finally PROGNOSIS in two less common forms of cancer (cholangiocarcinoma and small bowel cancer). Our goal is to be able to tailor individual patients' follow-up for gastrointestinal disease as well as their drug treatment to influence cancer development and mortality in gastrointestinal cancer. Our hope is that our project will lead to savings and make care more efficient. Furthermore, we want to conduct research that is relevant to the patient. Jonas Eriksson from the patient association Magtarmförbundet has participated in the planning of the studies (http://www.magotarm.se).
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2017 - 31 December 2019
  • Swedish Research Council
    1 January 2017 - 31 December 2020
  • Council for International Exchange of Scholars
    1 January 2012 - 30 April 2012
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2011 - 31 December 2013
  • Swedish Research Council
    1 January 2010 - 31 December 2010
  • Swedish Research Council
    1 January 2010 - 31 December 2013
  • Swedish Research Council
    1 January 2010 - 31 December 2013

Medarbetare och kontakt

Gruppledare

Alla medarbetare i gruppen

Besöksadress

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Nobels väg 12A, Stockholm, 171 77, Sweden

Postadress

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, PO Box 281, Stockholm, 171 77, Sweden

Nyckelord:
Eosinofili Epidemiologi Epidemiologi Fettlever Folkhälsovetenskap, global hälsa och socialmedicin Visa alla
Innehållsgranskare:
Jonas Ludvigsson
Gunilla Sonnebring
2025-09-04